+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Evidence to support IL-13 as a risk locus for psoriatic arthritis but not psoriasis vulgaris



Evidence to support IL-13 as a risk locus for psoriatic arthritis but not psoriasis vulgaris



Annals of the Rheumatic Diseases 70(6): 1016-1019



There is great interest in the identification of genetic factors that differentiate psoriatic arthritis (PsA) from psoriasis vulgaris (PsV), as such discoveries could lead to the identification of distinct underlying aetiological pathways. Recent studies identified single nucleotide polymorphisms (SNPs) in the interleukin 13 (IL-13) gene region as risk factors for PsV. Further investigations in one of these studies found the effect to be primarily restricted to PsA, thus suggesting the discovery of a specific genetic risk factor for PsA. Given this intriguing evidence, association to this gene was investigated in large collections of PsA and PsV patients and healthy controls. Two SNPs (rs20541 and rs1800925) mapping to the IL-13 gene were genotyped in 1057 PsA and 778 type I PsV patients using the Sequenom genotyping platform. Genotype frequencies were compared to those of 5575 healthy controls. Additional analyses were performed in phenotypic subgroups of PsA (type I or II PsV and in those seronegative for rheumatoid factor). Both SNPs were found to be highly associated with susceptibility to PsA (rs1800925 ptrend = 6.1 × 10(-5) OR 1.33, rs20541 ptrend = 8.0 × 10(-4) OR 1.27), but neither SNP was significantly associated with susceptibility to PsV. This study confirms that the effect of IL-13 risk locus is specific for PsA, thus highlighting a key biological pathway that differentiates PsA from PsV. The identification of markers that differentiate the two diseases raises the possibility in future of allowing screening of PsV patients to identify those at risk of developing PsA.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 036080156

Download citation: RISBibTeXText

PMID: 21349879

DOI: 10.1136/ard.2010.143123


Related references

PTPN22 is associated with susceptibility to psoriatic arthritis but not psoriasis: evidence for a further PsA-specific risk locus. Annals of the Rheumatic Diseases 74(10): 1882-1885, 2015

Investigation of 20 non-HLA psoriasis susceptibility loci in Chinese patients with psoriatic arthritis and psoriasis vulgaris. 2013

Clinical Risk Factors for the Development of Psoriatic Arthritis Among Patients with Psoriasis: A Review of Available Evidence. Current Rheumatology Reports 17(10): 64, 2016

Investigation of 20 non-HLA (human leucocyte antigen) psoriasis susceptibility loci in Chinese patients with psoriatic arthritis and psoriasis vulgaris. British Journal of Dermatology 168(5): 1060-1065, 2013

Lack of association of TNF-238A and -308A in Japanese patients with psoriasis vulgaris, psoriatic arthritis and generalized pustular psoriasis. Journal of Dermatological Science 29(3): 181-184, September, 2002

New psoriasis treatments based upon a deeper understanding of the pathogenesis of psoriasis vulgaris and psoriatic arthritis: a personal appraisal of their use in practice. Journal of the American Academy of Dermatology 49(2): 351-356, 2003

US Perspectives in the Management of Psoriasis and Psoriatic Arthritis: Patient and Physician Results from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey. American Journal of Clinical Dermatology 17(1): 87-97, 2016

Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey. Journal of the European Academy of Dermatology and Venereology 29(10): 2002-2010, 2016

(18)FDG PET/CT is a powerful tool for detecting subclinical arthritis in patients with psoriatic arthritis and/or psoriasis vulgaris. Journal of Dermatological Science 64(2): 144-147, 2012

Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. Journal of the American Academy of Dermatology 65(1): 137-174, 2011

Single nucleotide polymorphisms in the tumor necrosis factor-alpha gene promoter region alter the risk of psoriasis vulgaris and psoriatic arthritis: a meta-analysis. Plos One 8(5): E64376, 2014

Neutrophilic cholangitis in psoriasis vulgaris and psoriatic arthritis. British Journal of Dermatology 168(1): 216-218, 2013

Therapy of psoriasis vulgaris and psoriatic arthritis with etanercept. Journal der Deutschen Dermatologischen Gesellschaft 3(6): 470-472, 2005

Nail dystrophies, scalp and intergluteal/perianal psoriatic lesions: risk factors for psoriatic arthritis in mild skin psoriasis?. Giornale Italiano di Dermatologia E Venereologia 149(2): 177-184, 2014